Literature DB >> 14452314

Accelerated turnover of phosphoribosylpyrophosphate, a purine nucleotide precursor, in certain gouty subjects.

O W JONES, D M ASHTON, J B WYNGAARDEN.   

Abstract

Entities:  

Keywords:  GOUT/metabolism; NUCLEOSIDES AND NUCLEOTIDES/metabolism

Mesh：

Substances：

Year:  1962        PMID： 14452314      PMCID： PMC291102          DOI： 10.1172/JCI104638

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  28 in total

1.  The pathogenesis of gout.

Authors:  J B WYNGAARDEN; O W JONES
Journal:  Med Clin North Am       Date:  1961-09       Impact factor: 5.456

2.  On the dual etiology of hyperuricemia in primary gout.

Authors:  J B WYNGAARDEN
Journal:  Arthritis Rheum       Date:  1960-10

3.  Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout.

Authors:  A B GUTMAN; T F YU
Journal:  Am J Med       Date:  1957-10       Impact factor: 4.965

4.  Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects.

Authors:  J PREISS; P HANDLER
Journal:  J Biol Chem       Date:  1958-08       Impact factor: 5.157

5.  Normal glycine-C14-incorporation into uric acid in primary gout.

Authors:  J B WYNGAARDEN
Journal:  Metabolism       Date:  1958-07       Impact factor: 8.694

6.  Biosynthesis of the purines. XXI. 5-Phosphoribosylpyrophosphate amidotransferase.

Authors:  S C HARTMAN; J M BUCHANAN
Journal:  J Biol Chem       Date:  1958-08       Impact factor: 5.157

7.  Studies of ribose metabolism. II. A method for the study of ribose synthesis in vivo.

Authors:  H H HIATT
Journal:  J Biol Chem       Date:  1957-12       Impact factor: 5.157

8.  The oxidation of histamine to imidazoleacetic acid in vivo.

Authors:  A H MEHLER; H TABOR; H BAUER
Journal:  J Biol Chem       Date:  1952-05       Impact factor: 5.157

9.  A new test for ergothioneine upon which is based a method for its estimation in simple solution and in blood-filtrates.

Authors:  G Hunter
Journal:  Biochem J       Date:  1928       Impact factor: 3.857

10.  Incorporation of glycine nitrogen into uric acid in normal and gouty man.

Authors:  J D BENEDICT; M ROCHE; T F YU; E J BIEN; A B GUTMAN; D STETTEN
Journal:  Metabolism       Date:  1952-01       Impact factor: 8.694
View more
  8 in total

Review 1.  INHERITED ENZYME DEFECTS: A REVIEW.

Authors:  T HARGREAVES
Journal:  J Clin Pathol       Date:  1963-07       Impact factor: 3.411

2.  Characterization of a feedback-resistant phosphoribosylpyrophosphate synthetase from cultured, mutagenized hepatoma cells that overproduce purines.

Authors:  C D Green; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

Review 3.  Pathophysiology of hyperuricemia in primary gout.

Authors:  J B Wyngaarden
Journal:  Trans Am Clin Climatol Assoc       Date:  1970

4.  A reappraisal of the concept of an abnormality of glutamine metabolism in primary gout.

Authors:  J B Wyngaarden; O Sperling; F Starmer
Journal:  Trans Am Clin Climatol Assoc       Date:  1973

5.  Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction.

Authors:  M A Becker
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

6.  Uric acid production with particular reference to the role of xanthine oxidase and its inhibition.

Authors:  R W Watts
Journal:  Proc R Soc Med       Date:  1966-04

7.  The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout.

Authors:  O Sperling; J B Wyngaarden; C F Starmer
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

8.  Hypoxanthine-guanine phosphoribosyltransferase. Characterization of a mutant in a patient with gout.

Authors:  I H Fox; I L Dwosh; P J Marchant; S Lacroix; M R Moore; S Omura; V Wyhofsky
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.